New Stanford Study Supports Personalized Prostate Cancer Mapping Through Machine Learning

Stanford University School of Medicine’s Department of Urology has published a new study in the European Urology Open Science journal highlighting the effectiveness of Avenda Health’s artificial intelligence (AI) model, Unfold AI, in identifying the extent of prostate cancer. The study found that Unfold AI is effective in encapsulating all of the clinically significant cancer within the prostate. In 80% of cases, Unfold AI identified clinically significant prostate cancer, significantly higher than conventional margins, which was only 56%. Dr. Brittany Wenger, co-founder and CEO of Avenda Health, said the validation of their AI mapping platform represents a shift from the standard of treating the entire prostate, which results in nearly 50% of patients losing their sexual or urinary function. She added that personalized care needs to be provided to achieve the goal of improving quality of life, and preventing recurrence.